Abstracts tagged "Allopurinol and gout"

Abstract Number: 1105 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol at higher than CrCL based doses remains controversial due to concerns over increased risk of adverse events (AE). A recent 12month randomized controlled…
Abstract Number: 1138 • 2017 ACR/ARHP Annual Meeting
Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout
Xiaomin Li¹, Qiujing Wei², Naomi Schlesinger³ and Jieruo Gu², ¹Rheumatology, Third affiliated hospital of Sun Yat-sen University, Guangzhou, China, ²Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Allopurinol, effectively regulates and controls serum uric acid levels but may cause allopurinol-induced life-threating severe cutaneous adverse reaction (SCAR). Previous studies reported that single…
Abstract Number: 3078 • 2015 ACR/ARHP Annual Meeting
ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout
Lisa K. Stamp¹, Mary Wallace², Tony R. Merriman³, Amanda Phipps-Green⁴, Ruth Topless^4,5, Jill Drake⁶, Paul Tan⁷, Nicola Dalbeth⁸ and Rebecca Roberts⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁷University of Auckland, Auckland, New Zealand, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Many patients fail to reach target serum urate (SU) on allopurinol. Although the most common causes of inadequate response are non-adherence and low dosing…